9th Tumor Models San Francisco Summit 2025

Memo

Waves of new models are being validated. A wider industry shift to precision oncology is requiring more specific genetic models. Availability and cost-effectiveness of sequencing and computational tools are enabling better and more accessible characterization of therapeutic pathways than ever before. The challenges and opportunities in preclinical and translational research are constantly evolving, and it has never been more critical to benchmark and share cross-industry learnings and case studies to de-risk the move to the clinic. Reuniting 180+ Preclinical, Translational, Discovery, Pharmacology, and Biology experts to share case studies in improving target selection, facilitating biomarker discovery, and achieving clinical translatability, the 9th Tumor Models San Francisco Summit is the definitive industry forum uniting the West Coast ecosystem of pharma and biotech to collaboratively advance the frontier of oncology research to the clinic. URLs:Tickets: https://go.evvnt.com/2714164-2?pid=5569Brochure: https://go.evvnt.com/2714164-3?pid=5569 Date and Time: Wednesday, 29 January 2025 at 08:00 to Thursday, 30 January 2025 at 14:30 Venue details: Grand Hyatt San Francisco, 345 Stockton Street, San Francisco, California, 94108, United States Category: Conferences Prices:Solution Provider/Vendor Pricing - Conference Only: USD 3699.00,Drug Developers and Researchers - Conference Only : USD 0.50 Speakers: Abhisek Mitra, Associate Director, AstraZeneca, Hongyu Xue, Director, In Vivo Pharmacology and Oncology Research, Bayer, Jie Zhang, Associate Scientist, Adicet Bio, Joseph, Reddy Director - Pharmacology, Astellas, Kimberly Schluns, Senior Director Research, Kite Pharma, Liam Jenkins, Associate Director, AstraZeneca, Mike Liao, Vice President, Clinical Pharmacology, Third Arc Bio, Nichole Escalante, Senior Scientist and Group Lead - In Vivo Pharmacology and Pharmacokinetics Multispecific Antibody Therapeutics, Zymeworks, Nicole Sodir, Senior Scientist II, Revolution Medicines, Pan Pan, Associate Director, AstraZeneca, Pengyu Huang, Principal Scientist and Head of In Vivo Pharmacology, Simnova Biotherapeutics, Poonam Yakkundi, Associate Director, In Vivo team lead, IGM Biosciences, Ramandeep Bhavsar, Senior Specialist, R and D, Regeneron, Si Wu, Senior Bioinformatics Scientist - Computational Oncology, Abbvie, Stephanie Casey Parks, Senior Principal Scientist, Amgen, Tim Sproul, Director, Atomic AI